Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 10/20 | 0.59 |
| ▸ | GRIK2 | Q13002 | 10/20 | 0.59 |
| ▸ | HTR2A | P28223 | 3/20 | 0.55 |
| ▸ | PAM | P19021 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CTSC | P53634 | 1/20 | 0.48 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3020748 | 1.00 | GRIK1 (0.59) | GRIK1GRIK2HTR2APAMGLA | |
| SCHEMBL6188960 | 0.84 | GRIK1 (0.54) | GRIK1GRIK2HTR2APAMGLA | |
| SCHEMBL27820312 | 0.84 | HTR2A (0.58) | GRIK1GRIK2HTR2APAMGLA | |
| SCHEMBL6188957 | 0.84 | GRIK1 (0.54) | GRIK1GRIK2HTR2APAMGLA | |
| SCHEMBL13235939 | 0.84 | HTR2A (0.58) | GRIK1GRIK2HTR2APAMGLA | |
| SCHEMBL28839683 | 0.83 | GRIK1 (0.45) | GRIK1GRIK2HTR2APAMCTSC | |
| SCHEMBL1716930 | 0.82 | GRIK1 (0.65) | GRIK1GRIK2HTR2APAMCTSC | |
| SCHEMBL28581078 | 0.82 | HTR2A (0.51) | GRIK1GRIK2HTR2APAMGLA | |
| SCHEMBL13944311 | 0.82 | HTR2A (0.51) | GRIK1GRIK2HTR2APAMGLA | |
| SCHEMBL1716932 | 0.82 | GRIK1 (0.65) | GRIK1GRIK2HTR2APAMCTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117917276-A | Composite solid acid catalyst, preparation method and application thereof | 中国石油化工股份有限公司 | 2024-04-23 | — | — | CN | disclosed |
| US-20130273798-A1 | ANTI-ALLERGEN AGENT | TOAGOSEI CO., LTD. (JP) | 2013-10-17 | — | — | US | disclosed |
| US-20100209530-A1 | ANTI-ALLERGEN AGENT | TOAGOSEI CO., LTD. (JP) | 2010-08-19 | — | — | US | disclosed |
| EP-1754700-A2 | Synthesis of oligoketides | Kosan Biosciences, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| US-7022825-B2 | Polyketides and antibiotics | KOSAN BIOSCIENCES, INC. (US) | 2006-04-04 | — | — | US | disclosed |
| EP-1471923-A4 | AMIDO MACROLIDES | KOSAN BIOSCIENCES INC (US) | 2006-01-11 | — | — | EP | disclosed |
| US-6939861-B2 | Amido macrolides | KOSAN BIOSCIENCES, INC. (US) | 2005-09-06 | — | — | US | disclosed |
| EP-1471923-A1 | AMIDO MACROLIDES | Kosan Biosciences, Inc. (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20030199458-A1 | Amido macrolides | KOSAN BIOSCIENCES, INC. | 2003-10-23 | — | — | US | disclosed |
| WO-2003061671-A1 | AMIDO MACROLIDES | KOSAN BIOSCIENCES, INC. (US) | 2003-07-31 | — | — | WO | disclosed |
| US-20030096374-A1 | Preparation of ketide ester; obtain benzoxazolone derivative, incubate with polyketide synthase, recover ketide oligomer | ASHLEY GARY (US) | 2003-05-22 | — | — | US | disclosed |
| US-20030092140-A1 | Novel polyketides and antibiotics | ASHLEY GARY (US) | 2003-05-15 | — | — | US | disclosed |
| EP-1144375-A2 | SYNTHESIS OF OLIGOKETIDES | Kosan Biosciences (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000044717-A9 | SYNTHESIS OF OLIGOKETIDES | — | 2001-08-23 | — | — | WO | disclosed |
| WO-2000044717-A2 | SYNTHESIS OF OLIGOKETIDES | KOSAN BIOSCIENCES, INC. (US) | 2000-08-03 | — | — | WO | disclosed |
| US-5360775-A | Porous clay intercalation compound and its production method | MITSUBISHI MATERIAL CORPORATION (JP) | 1994-11-01 | — | — | US | disclosed |
| US-5013709-A | Acid-treated smectite clay mineral | MIZUSAWA INDUSTRIAL CHEMICALS, LTD. (JP) | 1991-05-07 | — | — | US | disclosed |
| US-4709024-A | REARRANGEMENT OF CYCLOHEXANONE OXIME | SUMITOMO CHEMICAL COMPANY (JP) | 1987-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199458-A1 | Amido macrolides | PCSK9, ABCB4, PCSK7 | GRIK1 3496/4885GRIK2 4038/4885HTR2A 2091/4885 |
| US-20030096374-A1 | Preparation of ketide ester; obtain benzoxazolone derivative, incubate with polyketide synthase, recover ketide oligomer | COASY, KARS1, ACOT7 | GRIK1 871/4885GRIK2 852/4885HTR2A 3030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.